Sign In
Buy PBYI
$8.04
+0.380 (+4.96%)
At Close: Jun 23, 2026
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up
11:35am, Friday, 08'th Nov 2024
Puma Biotechnology beats third-quarter 2024 estimates for both the top and the bottom lines. The company updates its 2024 financial guidance.
Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript
11:09pm, Thursday, 07'th Nov 2024
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - CEO, President and Cha
Puma Biotech (PBYI) Q3 Earnings and Revenues Surpass Estimates
07:41pm, Thursday, 07'th Nov 2024
Puma Biotech (PBYI) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.17 per share a year ago.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Tuesday, 05'th Nov 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 4, 2024, the Compensation Committee of Puma's Board of Directors approved
PHILADELPHIA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Puma Biotechnology, Inc. (“Puma”) (NASDAQ: PBYI) on behalf of the company's shareholders.
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected
11:10am, Friday, 02'nd Aug 2024
Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.
Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript
10:54pm, Thursday, 01'st Aug 2024
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2024 Earnings Call August 1, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chief Executive Off
Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates
07:11pm, Thursday, 01'st Aug 2024
Puma Biotech (PBYI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to earnings of $0.10 per share a year ago.
Puma Biotechnology Reports Second Quarter Financial Results
04:05pm, Thursday, 01'st Aug 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its second quarter financial results and hosted a conference call on August 1, 2024.
Bet on These 4 Top-Performing Liquid Stocks for Solid Gains
08:31am, Thursday, 01'st Aug 2024
Liquidity indicates a company's capability to meet debt obligations by converting its assets into liquid cash and equivalents.
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
10:45am, Tuesday, 23'rd Jul 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
04:10pm, Thursday, 18'th Jul 2024
LOS ANGELES--(BUSINESS WIRE)--On Aug. 1, Puma Biotechnology will issue its earnings results for the 2024 second quarter and follow with a conference call to discuss the results.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Tuesday, 02'nd Jul 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology granted an inducement award to one new employee, who was hired in June 2024.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:37pm, Friday, 07'th Jun 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 6, 2024, the Compensation Committee of Puma's Board of Directors approved the
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
02:33pm, Monday, 03'rd Jun 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology Announced Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer at the 2024 ASCO Annual Meeting.
